Novel Microglia Cell Line Expressing the Human EP2 Receptor

Area of Science:

• Neuroscience
• Immunology
• Cell Biology

Background:

• Microglial cells are crucial for brain immunity but challenging to study due to isolation difficulties and limited lifespan.
• EP2 signaling pathways regulate microglial activation and death, but their function in cell lines is not well-established.
• A reliable microglial cell line model is needed to overcome limitations of primary cultures for studying EP2 modulation.

Purpose of the Study:

• To establish and characterize a murine BV2 microglial cell line stably expressing human EP2 receptors (BV2-hEP2).
• To investigate the role of EP2 receptor activation in modulating microglial immune responses and phagocytic functions.
• To assess the utility of the BV2-hEP2 cell line as a model for studying EP2 signaling in microglia.

Main Methods:

• Stable transfection of BV2 cells with human EP2 receptors to create the BV2-hEP2 cell line.
• Stimulation with selective EP2 receptor agonists and antagonists to assess receptor activity via cAMP assays.
• Treatment with lipopolysaccharide (LPS) to induce inflammatory responses (COX-2, IL-1β, TNFα, IL-6) and phagocytosis assays.

Main Results:

• BV2-hEP2 cells showed EP2-specific cAMP elevation, inhibited by EP2 antagonists, unlike untransfected BV2 cells.
• EP2 activation modulated LPS-induced inflammatory mediator production, depressing TNFα but exacerbating others.
• The presence of EP2 in BV2-hEP2 cells reduced phagocytosis and proliferation, independent of classical EP2 signaling.

Conclusions:

• The BV2-hEP2 cell line effectively models EP2 modulation of microglial immune regulation and phagocytic function.
• EP2 protein presence, not just activation, suppresses microglial phagocytosis, suggesting novel therapeutic targets.
• This cell line provides a valuable tool for advancing research into EP2 signaling in neuroinflammation and therapeutics.